Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics


Halozyme Therapeutics, Inc. (HALO)

Today's Latest Price: $27.90 USD

0.09 (-0.32%)

Updated Jul 10 4:00pm

Add HALO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

HALO Stock Summary

  • HALO's price/sales ratio is 23.05; that's higher than the P/S ratio of 93.32% of US stocks.
  • With a year-over-year growth in debt of 269.46%, Halozyme Therapeutics Inc's debt growth rate surpasses 94.21% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Halozyme Therapeutics Inc is reporting a growth rate of 91.41%; that's higher than 88.32% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Halozyme Therapeutics Inc are LJPC, FGEN, PZG, RARE, and HRTX.
  • Visit HALO's SEC page to see the company's official filings. To visit the company's web site, go to www.halozyme.com.
HALO Daily Price Range
HALO 52-Week Price Range

HALO Stock Price Chart Technical Analysis Charts


HALO Price/Volume Stats

Current price $27.90 52-week high $29.34
Prev. close $28.00 52-week low $12.71
Day low $27.80 Volume 691,602
Day high $28.29 Avg. volume 1,652,017
50-day MA $24.61 Dividend yield N/A
200-day MA $19.82 Market Cap 3.79B

Halozyme Therapeutics, Inc. (HALO) Company Bio


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.


HALO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

HALO Latest Social Stream


Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Drug Stock May Be Overdue for a Short Squeeze

Halozyme Therapeutics flashed a bull signal that could push the security to fresh record highs

Schaeffers Investment Research | July 9, 2020

Edited Transcript of HALO.OQ earnings conference call or presentation 11-May-20 8:30pm GMT

Q1 2020 Halozyme Therapeutics Inc Earnings Call

Yahoo | July 1, 2020

Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations

I have always stuck up for Western medicine. You can chew all the celery you want, but without antibiotics, three quarters of us would not be here. ~ Hugh Laurie The prospects of Halozyme Therapeutics (HALO) look exciting, but its negative cash flows from operations and stock repurchases are funded...

Michael A. Gayed, CFA on Seeking Alpha | June 30, 2020

Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, a fixed-dose combination (FDC) of Perjeta® and Herceptin® with Halozyme's ENHANZE® technology, administered subcutaneously in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with early and metastatic HER2-positive breast cancer. This is the first time a product has been approved combining two monoclonal antibodies that can be administered by a single subcutaneous injection utilizing Halozyme's ENHANZE® technology.

Yahoo | June 29, 2020

Halozyme To Receive $10 Million Milestone Payment From Janssen

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $10 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The milestone payment is associated with the first commercial sale in the European Union of Janssen's subcutaneous formulation of DARZALEX® (daratumumab) utilizing ENHANZE®, which was recently granted marketing authorization by the European Commission.

Yahoo | June 22, 2020

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 22.26%
3-mo 54.83%
6-mo 40.34%
1-year 68.28%
3-year 111.20%
5-year 16.40%
YTD 57.36%
2019 21.19%
2018 -27.79%
2017 105.06%
2016 -42.99%
2015 79.59%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.887 seconds.